| Date | Title | |
| 11/14/08 | Gilead Sciences Announces Notification of ANDA Filing for Truvada |  |
| 11/05/08 | Gilead Sciences to Present at Three Upcoming Investor Conferences | |
| 11/01/08 | Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B | |
| 10/30/08 | Gilead Sciences to Present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4 | |
| 10/28/08 | Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1) | |
| 10/23/08 | Gilead Signs Agreement with EFI to Acquire Building and Associated Land Bordering Gilead's Foster City Campus | |
| 10/16/08 | Gilead Sciences Announces Third Quarter 2008 Financial Results | |
| 10/09/08 | Gilead Sciences to Release Third Quarter 2008 Financial Results on Thursday, October 16, 2008 | |
| 09/16/08 | Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhalation, an Investigational Treatment for Cystic Fibrosis | |
| 09/11/08 | Seigo Izumo, MD Joins Gilead as Senior Vice President, Cardiovascular Therapeutics | |
| 09/10/08 | Gilead Sciences to Present at Two Upcoming Investor Conferences | |
| 08/27/08 | Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3 | |
| 08/11/08 | U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults | |
| 08/01/08 | Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries | |
| 07/31/08 | Richard J. Whitley, MD Joins Gilead Sciences' Board of Directors | |
| 07/22/08 | Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV | |
| 07/17/08 | Gilead Sciences Announces Second Quarter 2008 Financial Results | |
| 07/08/08 | Gilead Sciences to Release Second Quarter 2008 Financial Results on Thursday, July 17, 2008 | |
| 06/13/08 | Gilead Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis | |
| 06/04/08 | Gilead Sciences to Present at the 29th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11 | |
| 06/02/08 | U.S. Patent Office Confirms Second of Four Viread(R) Patents | |
| 05/29/08 | Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension | |
| 05/29/08 | Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation | |
| 05/22/08 | Gilead Sciences' Chairman and Chief Executive Officer Establishes Rule 10b5-1 Stock Trading Plan | |
| 05/20/08 | U.S. Patent Office Confirms First of Four Viread(R) Patents | |
| 05/20/08 | Gilead Announces New Letairis(R) (Ambrisentan) Data for the Treatment of Patients With Pulmonary Arterial Hypertension (WHO Group 1) With WHO Functional Class II or III Symptoms | |
| 05/14/08 | Gilead Sciences to Present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21 | |
| 05/13/08 | Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan | |
| 05/09/08 | Gilead Sciences to Present at the Bank of America 2008 Healthcare Conference on Tuesday, May 13 | |
| 05/07/08 | Gilead Appoints John C. Martin as Chairman of Board of Directors; Names John F. Milligan President | |
| 05/01/08 | Gilead Initiates Letairis(R) (ambrisentan) Phase IV Program | |
| 04/25/08 | European Commission Approves Viread(R) for Chronic Hepatitis B | |
| 04/24/08 | Gilead Sciences to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30 | |
| 04/24/08 | Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B | |
| 04/21/08 | Robin L. Washington to Join Gilead as Senior Vice President and Chief Financial Officer | |
| 04/16/08 | Gilead Sciences Announces First Quarter 2008 Financial Results | |
| 04/09/08 | Gilead Sciences to Release First Quarter 2008 Financial Results on Wednesday, April 16, 2008 | |
| 03/19/08 | European CHMP Issues Positive Opinion for Viread(R) for the Treatment of Chronic Hepatitis B | |
| 03/10/08 | Gilead Sciences to Present at Two Upcoming Investor Conferences | |
| 03/07/08 | Gilead Sciences Submits Marketing Authorisation Application for Aztreonam Lysine 75 mg Powder for Nebuliser Solution, a Potential New Treatment for Cystic Fibrosis, to European Medicines Agency | |
| 03/06/08 | Gilead Appoints Dr. John J. Toole as Senior Vice President, Corporate Development | |
| 02/29/08 | Gilead Announces $500 Million Accelerated Share Repurchase | |
| 01/30/08 | Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5 | |
| 01/23/08 | Gilead Sciences Announces Fourth Quarter and Full Year 2007 Financial Results | |
| 01/21/08 | Gilead Announces Departure of Caroline Dorsa | |
| 01/16/08 | Gilead Sciences to Release Fourth Quarter and Year End 2007 Financial Results on Wednesday, January 23, 2008 | |
| 01/03/08 | Gilead Sciences to Present at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7 | |
